Urovant Sciences Ltd (NASDAQ:UROV) major shareholder Holdings Ltd. Dexxon bought 11,608 shares of the firm’s stock in a transaction that occurred on Friday, May 17th. The stock was bought at an average price of $7.10 per share, with a total value of $82,416.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

NASDAQ:UROV opened at $7.64 on Thursday. Urovant Sciences Ltd has a 12-month low of $4.05 and a 12-month high of $14.49.

A number of institutional investors have recently bought and sold shares of UROV. BlackRock Inc. acquired a new stake in Urovant Sciences in the third quarter valued at $4,574,000. Man Group plc acquired a new stake in Urovant Sciences in the third quarter valued at $300,000. Sphera Funds Management LTD. raised its stake in Urovant Sciences by 30.5% in the fourth quarter. Sphera Funds Management LTD. now owns 214,030 shares of the company’s stock valued at $1,410,000 after buying an additional 50,000 shares in the last quarter. Barclays PLC acquired a new stake in Urovant Sciences in the fourth quarter valued at $37,000. Finally, Weiss Multi Strategy Advisers LLC raised its stake in Urovant Sciences by 38.2% in the fourth quarter. Weiss Multi Strategy Advisers LLC now owns 15,000 shares of the company’s stock valued at $99,000 after buying an additional 4,146 shares in the last quarter. Institutional investors own 24.83% of the company’s stock.

A number of research analysts recently issued reports on the company. Zacks Investment Research upgraded Urovant Sciences from a “hold” rating to a “buy” rating and set a $9.75 target price for the company in a report on Thursday, April 18th. HC Wainwright reiterated a “buy” rating and issued a $28.00 target price on shares of Urovant Sciences in a report on Friday, March 22nd. Finally, SunTrust Banks assumed coverage on Urovant Sciences in a report on Friday, March 15th. They issued a “buy” rating and a $24.00 target price for the company. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $21.13.

ILLEGAL ACTIVITY NOTICE: “Urovant Sciences Ltd (UROV) Major Shareholder Acquires $82,416.80 in Stock” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.watchlistnews.com/urovant-sciences-ltd-urov-major-shareholder-acquires-82416-80-in-stock/3019764.html.

About Urovant Sciences

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.

Recommended Story: Dollar Cost Averaging

Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.